Entry Point Capital, LLC Replimune Group, Inc. Transaction History

Entry Point Capital, LLC

  • $171 Million
  • Q3 2024

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024
SELL
$5.01 - $9.46 $48,361 - $91,317
-9,653 Reduced 54.52%
8,051 $72.5 Million
Q1 2024

May 14, 2024
SELL
$6.87 - $9.31 $83,525 - $113,190
-12,158 Reduced 40.71%
17,704 $145 Million
Q4 2023

Feb 14, 2024
BUY
$6.75 - $16.18 $201,568 - $483,167
29,862 New
29,862 $252 Million

Others Institutions Holding REPL

# of Institutions
149
Shares Held
68M
Call Options Held
52.3K
Put Options Held
80.3K
View Full List

About Replimune Group, Inc.

REPL Quotes by TradingView
  • Ticker REPL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 49,306,700
  • Market Cap $616M
  • Description
  • Replimune Group, Inc., a biotechnology company, develops oncolytic immuno-gene therapies to treat cancer. It uses its proprietary Immunotherapy platform to design and develop product candidates that are intended to activate the immune system against cancer. The company's lead product candidate is RP1, a selectively replicating version of herpes ...
More about REPL
Track This Portfolio

Track Entry Point Capital, LLC Portfolio

Follow Entry Point Capital, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Entry Point Capital, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Entry Point Capital, LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email